Related Experiment Video
Updated: Jun 28, 2025
07:38
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
3.5K
Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and
Rahul Vyas1, Viraj Panchal2, Shubhika Jain3
1Department of Internal Medicine, Louisiana State University, Shreveport, Louisiana, United States of America.
Plos One
|April 18, 2024
Summary
Mavacamten significantly improved hypertrophic cardiomyopathy (HCM) symptoms and cardiac function compared to placebo. While generally safe, further large-scale trials are recommended to fully assess Mavacamten
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Hypertrophic Cardiomyopathy (HCM) is a genetic heart muscle disease characterized by left ventricular outflow tract (LVOT) obstruction.
- Mavacamten, a novel cardiac myosin inhibitor, is being investigated for HCM treatment.
- This meta-analysis evaluates Mavacamten's efficacy and safety against placebo in HCM patients.
Approach:
- A systematic meta-analysis of five Phase 3 randomized controlled trials (RCTs) from 2010-2023.
- Searched PubMed, Cochrane, and clinicaltrials.gov for relevant studies.
- Employed Mantel-Haenszel and Generic Inverse Variance methods for pooled analysis using RevMan.
Key Points:
- Mavacamten significantly improved New York Heart Association (NYHA) grade (OR 4.94) and KCCQ scores (OR 7.93).
- Observed significant reductions in LVOT obstruction, LAVI, and LVEF, alongside decreased NT-proBNP and troponin-I levels.
- No statistically significant differences in treatment-emergent adverse events (TEAEs) or serious adverse events (TSAEs) were noted between groups.
Conclusions:
- Mavacamten demonstrates comprehensive benefits for HCM, impacting structural and functional cardiac aspects.
- The drug shows a favorable efficacy and safety profile in the analyzed patient population.
- Further extensive clinical trials are warranted to solidify Mavacamten's long-term safety profile.
